5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: A systematic review and meta-analysis

International Journal of Neuropsychopharmacology

Volumn 17, Issue 5, 2014, Pages 823-832

  Laoutidis, Zacharias G ^a   Luckhaus, Christian ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Akathisia; extrapyramidal side effects; serotonin receptor antagonists

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYPROHEPTADINE; MIANSERIN; MIRTAZAPINE; NEUROLEPTIC AGENT; PROPRANOLOL; SEROTONIN 2A ANTAGONIST; TRAZODONE; SEROTONIN 2 ANTAGONIST;

AKATHISIA; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HUMAN; META ANALYSIS; NEUROLEPTIC INDUCED AKATHISIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; AKATHISIA, DRUG-INDUCED;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84898057496     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001417     Document Type: Review

References (46)

1. Adler L, Angrist B, Peselow E, Corwin J, Maslansky R, Rotrosen J (1986) A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 149:42-45
2. Amadasi A, Bertoldi M, Contestabile R, Bettati S, Cellini B, di Salvo ML, Borri-Voltattorni C, Bossa F, Mozzarelli A (2007) Pyridoxal 5'-phosphate enzymes as targets for therapeutic agents. Curr Med Chem 14:1291-1324
3. American Psychiatric Association (2000). Appendix B: Criteria sets and axes provided for further study. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. Washington, DC: American Psychiatric Association
4. Avital A, Gross-Isseroff R, Stryjer R, Hermesh H, Weizman A, Shiloh R (2009) Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: A comparative double-blind study. Eur Neuropsychopharmacol 19:476-482
5. Bakker PR, Al Hadithy AF, Amin N, van Duijn CM, van Os J, van Harten PN (2012) Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 tag SNPs in 7 candidate genes: A prospective study. PLoS One; 7(12): E50970. doi: 10.1371/journal.pone.0036561
6. Barnes TRE, Soares-Weiser K, Bacaltchuk J (2004) Central action beta-blockers vs. placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev Issue 4. Art. No.: CD001946. doi:10.1002/14651858.CD001946. pub2
7. Borenstein M, Hedges RV, Higgins JPT, Rothstein HR (2009) Introduction to Meta-Analysis. West Sussex: Wiley Edition
8. Braude WM, Barnes TR, Gore SM (1983) Clinical characteristics of akathisia: A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 143:139-150
9. Crane GE, Naranjo ER, Chase TN (1971) Motor disorder induced by neuroleptics. Arch Gen Psychiatry 24:179-184
10. Dépatie L, Lal S (2001) Apomorphine and the dopamine hypothesis of schizophrenia: A dilemma? J Psychiatry Neurosci 26:203-220
11. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-Analysis detected by a simple graphical test. BMJ 315:629-634
12. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A (2002) Meta-Analyses involving cross-over trials: Methodological issues. Int J Epidemiol 31:140-149
13. Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S (2012) Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 26:1033-1049
14. Fischel T, Hermesh H, Aizenberg D, Zemishlany Z, Munitz H, Benjamini Y, Weizman A (2001) Cyproheptadine vs. propranolol for the treatment of acute neuroleptic-induced akathisia: A comparative double-blind study. J Clin Psychopharmacol 21:612-615
15. Friedrich JO, Adhikari NKJ, Beyene J (2007) Inclusion of zero total event trials in meta-Analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 7:5. doi:10.1186/1471-2288-7-5
16. Haddad PM, Das A, Keyhani S, Chaudhry IB (2012) Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: A systematic review of head-head comparisons. J Psychopharmacol 26:15. doi: 10.1177/ 0269881111424929
17. Halstead SM, Barnes TRE, Speller JC (1994) Akathisia prevalence and associated dysphoria in an inpatient population with chronic schizophrenia. Br J Psychiatry 163:177-183
18. Higgins JPT, Green S (editors) (2008) Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, Ltd
19. Irwin M, Sullivan G, Van Putten T (1988) Propranolol as a primary treatment of neuroleptic-induced akathisia. Hillside J Clin Psychiatry 10:244-250
20. Koliscak LP, Makela EH (2009) Selective serotonin reuptake inhibitor-induced akathisia. J Am Pharm Assoc 49:e28-e36; quiz e37-e38. doi:10.1331/JAPhA.2009.08083
21. Kramer MS, Gorkin RA, DiJohnson C, Sheves P (1988) Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: A double-blind, placebo-controlled study. Biol Psychiatry 24:823-827
22. Lerner V, Miodownik C, Kaptsan A, Cohen H, Matar M, Loewenthal U, Kotler M (2001) Vitamin B6 in the treatment of tardive dyskinesia: A double-blind, placebo-controlled, crossover study. Am J Psychiatry 158:1511-1514
23. Lerner V, Bergman J, Statsenko N, Miodownik C (2004) Vitamin B6 treatment in acute neuroleptic-induced akathisia: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry 65:1550-1554
24. Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, Sela BA, Witztum E (2007) Vitamin B6 treatment for tardive dyskinesia: A randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry 68:1648-1654
25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223
26. Miller CH, Fleischhacker WW, Ehrmann H, Kane JM (1990) Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull 26:373-376
27. Miller CH, Hummer M, Oberbauer H, Kurzthaler I, DeCol C, Fleischhacker WW (1997) Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacol 7:51-55
28. Miodownik C, Lerner V, Statsenko N, Dwolatzky T, Nemets B, Berzak E, Bergman J (2006) Vitamin B6 vs. mianserin and placebo in acute neuroleptic-induced akathisia: A randomized, double-blind, controlled study. Clin Neuropharmacol 29:68-72
29. Mohr P, Voavka J (2002) Ladislav Haskovec and akathisia: 100th anniversary. Br J Psychiatry 181:537
30. Neyeloff JL, Fuchs SC, Moreira LB (2012) Meta-Analyses and forest plots using a microsoft excel spreadsheet: Step-by-step guide focusing on descriptive data analysis. BMC Res Notes 5:52, http://www.biomedcentral.com/1756-0500/5/52
31. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J (2006) Drug insight: From disturbed motility to disordered movement-A review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 3:138-148
32. Peluso MJ, Lewis SW, Barnes TRE, Jones PB (2012) Extrapyramidal motor side-effects of first-And second-generation antipsychotic drugs. Br J Psychiatry 200:387-392
33. Poyurovski M (2010) Acute antipsychotic induced akathisia revisited. Br J Psychiatry 196:89-91
34. Poyurovsky M, Shardorodsky M, Fuchs C, Schneidman M, Weizman A (1999) Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study. Br J Psychiatry 174:238-242
35. Poyurovsky M, Epshtein S, Fuchs C, Schneidman M,Weizman R, Weizman A (2003) Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: A double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 23:305-308
36. Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A (2006) Low-dose mirtazapine: A new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo-And propranolol-controlled trial. Biol Psychiatry 59:1071-1077
37. Rathbone J, Soares-Weiser K (2006) Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev Issue 4. Art. No.: CD003727. doi:10.1002/14651858. CD003727.pub3
38. Reiter S, Adler L, Angrist B, Corwin J, Rotrosen J (1987) Atenolol and propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 7:279-280
39. Resende Lima A, Soares-Weiser K, Bacaltchuk J, Barnes TRE (1999) Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev Issue 4. Art. No.: CD001950. doi:10.1002/14651858.CD001950
40. Rosenheck R, et al. (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomized controlled trial. JAMA 26;290:2693-2702
41. Sachdev P, Loneragan C (1993a) Intravenous benztropine and propranolol challenges in acute neuroleptic-induced akathisia. Clin Neuropharmacol 16:324-331
42. Sachdev P, Loneragan C (1993b) Low-dose apomorphine challenge in tardive akathisia. Neurology 43(3 Pt 1):544-547
43. Seemueller F, Schennach R, Mayr A, Musil R, Jaeger M, MaierW, Klingenberg S, Heuser I, Klosterkoetter J, Gastpar M, Schmitt A, Schloesser R, Schneider F, Ohmann C, Lewitzka U, Gaebel W, Moeller HJ, Riedel M, for the German Study Group on First-Episode Schizophrenia (2012) Akathisia and suicidal ideation in first-Episode schizophrenia. J Clin Psychopharmacol 32:694-698
44. Stahl SM (2008) Stahl's Essential Psychopharmacology. New York: Cambridge University Press
45. Stryjer R, Rosenzcwaig S, Bar F, Ulman AM, Weizman A, Spivak B (2010) Trazodone for the treatment of neuroleptic-induced acute akathisia: A placebo-controlled, double-blind, crossover study. Clin Neuropharmacol 33:219-222
46. Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A (1987) Clinical nonrecognition of neuroleptic induced movement disorders: A cautionary study. Am J Psychiatry 144:1148-1153